Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People of any gender
- People under 18 years of age
- People who have been diagnosed with acute myeloid leukemia (AML), a type of blood cancer, based on 2022 medical classification guidelines
- People whose AML has a specific genetic feature — either t(8;21)/RUNX1::RUNX1T1 or inv(16)/t(16;16)/CBFβ::MYH11 (confirm with trial site)
- People whose AML also has a specific gene change called a KIT mutation
- People whose AML did not respond to initial treatment (meaning the cancer did not go into remission after the first round of chemotherapy)
- People whose AML came back after previously going into remission following further treatment or a transplant, confirmed by specific genetic testing
- People who do not have an active infection at the time of joining
- People whose liver and kidney are working well enough to meet specific blood test levels (confirm with trial site)
- People who are fairly active and able to carry out daily activities (a medical scoring system called ECOG rates this as less than 2)
- People whose expected survival is more than 12 weeks
- People who are able to understand the study and are willing to sign a consent form agreeing to take part
Who may not be able to join:
- People who have previously been treated with a drug called avapritinib
- People who are currently receiving other targeted AML treatments at the same time, such as dasatinib, sorafenib, gilteritinib, or venetoclax
- People who have an active, uncontrolled infection (bacterial, fungal, or viral)
- People who have serious ongoing problems with the heart, liver, or kidneys, such as heart failure or a recent heart attack
- People who have another type of cancer that is currently being treated
- People who are already taking part in another clinical trial that involves a treatment or intervention
- People whom the trial researchers determine are not suitable for the study for other reasons
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Shaoyan Hu, MD, PhD, Children 's Hospital of Soochow University
Phone: +86-13771870462
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Composite remission rate (CRc)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.